Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Researchers at Stanford have developed chimeric antigen receptors (CARs) that target glypican-2 (GPC2) and can be used to treat solid tumors. CAR-engineered T cells have shown great promise as cancer therapeutics.